(Q33417569)

English

Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 July 2017

Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial (English)

1 reference

Europe PubMed Central

26 July 2017

phase II clinical trial

0 references

multicenter clinical trial

0 references

chemoradiotherapy

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

object named as

Jin-Hong Park

17

0 references

9

object named as

Tae-You Kim

1 reference

Europe PubMed Central

26 July 2017

author name string

Yong Sang Hong

1

1 reference

Europe PubMed Central

26 July 2017

Byung-Ho Nam

2

1 reference

Europe PubMed Central

26 July 2017

Kyu-Pyo Kim

3

1 reference

Europe PubMed Central

26 July 2017

Jeong Eun Kim

4

1 reference

Europe PubMed Central

26 July 2017

Seong Joon Park

5

1 reference

Europe PubMed Central

26 July 2017

Young Suk Park

6

1 reference

Europe PubMed Central

26 July 2017

Joon Oh Park

7

1 reference

Europe PubMed Central

26 July 2017

Sun Young Kim

8

1 reference

Europe PubMed Central

26 July 2017

Jee Hyun Kim

10

1 reference

Europe PubMed Central

26 July 2017

Joong Bae Ahn

11

1 reference

Europe PubMed Central

26 July 2017

Seok-Byung Lim

12

1 reference

Europe PubMed Central

26 July 2017

Chang Sik Yu

13

1 reference

Europe PubMed Central

26 July 2017

Jin Cheon Kim

14

1 reference

Europe PubMed Central

26 July 2017

Seong Hyeon Yun

15

1 reference

Europe PubMed Central

26 July 2017

Jong Hoon Kim

16

1 reference

Europe PubMed Central

26 July 2017

Hee Chul Park

18

1 reference

Europe PubMed Central

26 July 2017

Kyung Hae Jung

19

1 reference

Europe PubMed Central

26 July 2017

Tae Won Kim

20

1 reference

Europe PubMed Central

26 July 2017

publication date

4 September 2014

1 reference

Europe PubMed Central

26 July 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

26 July 2017

15

1 reference

Europe PubMed Central

26 July 2017

11

1 reference

Europe PubMed Central

26 July 2017

1245-1253

1 reference

Europe PubMed Central

26 July 2017

Colorectal cancer statistics, 2014.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970377-8

7 January 2021

based on heuristic

inferred from DOI database lookup

The surgeon as a prognostic factor after the introduction of total mesorectal excision in the treatment of rectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970377-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970377-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970377-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970377-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Pathologic nodal classification is the most discriminating prognostic factor for disease-free survival in rectal cancer patients treated with preoperative chemoradiotherapy and curative resection.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970377-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970377-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Does adjuvant fluoropyrimidine-based chemotherapy provide a benefit for patients with resected rectal cancer who have already received neoadjuvant radiochemotherapy? A systematic review of randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970377-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Postoperative adjuvant chemotherapy use in patients with stage II/III rectal cancer treated with neoadjuvant therapy: a national comprehensive cancer network analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970377-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Patients with rectal cancer receiving adjuvant chemotherapy have an increased survival: a population-based longitudinal study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970377-8

7 January 2021

based on heuristic

inferred from DOI database lookup

EURECCA colorectal: multidisciplinary management: European consensus conference colon & rectum

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970377-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970377-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970377-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970377-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970377-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III Trial of Capecitabine Plus Oxaliplatin As Adjuvant Therapy for Stage III Colon Cancer: A Planned Safety Analysis in 1,864 Patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970377-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Validation of the Korean version of the EORTC QLQ-C30.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970377-8

7 January 2021

based on heuristic

inferred from DOI database lookup

The construction and testing of the EORTC colorectal cancer-specific quality of life questionnaire module (QLQ-CR38). European Organization for Research and Treatment of Cancer Study Group on Quality of Life

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970377-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Canc

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970377-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Postoperative adjuvant chemotherapy in rectal cancer operated for cure

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970377-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970377-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970377-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970377-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy with preoperative radiotherapy in rectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970377-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970377-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970377-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970377-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970377-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970377-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970377-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Preoperative versus postoperative chemoradiotherapy for rectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970377-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(14)70377-8

1 reference

Europe PubMed Central

26 July 2017

1 reference

Europe PubMed Central

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33417569&oldid=1686998314"